If you have read three clinic websites about platelet-rich plasma, you have probably seen three different regulatory claims: "FDA-approved," "FDA-cleared," and "FDA-registered." Only one of those means much, and it doesn't mean what most patients think.

This is the single most misused piece of language in regenerative medicine marketing. It is worth ten minutes of your time before you spend four figures.

The short answer

PRP is not an FDA-approved treatment for hair loss, knee osteoarthritis, tendon injuries, facial rejuvenation, or sexual function. There is no FDA approval to point to for any of those uses.

What does exist: a number of blood-separation systems — the centrifuges, tubes, and kits used to spin your blood down into a platelet concentrate — have been cleared by the FDA as medical devices. Clearance of the equipment is not approval of the therapy.

A clinic that says "we use an FDA-cleared PRP system" is likely telling the truth. A clinic that says "PRP is FDA-approved" is not.

Two different FDA pathways, and only one is "approval"

Device clearance, via 510(k)

Most PRP preparation systems reach the market through the 510(k) premarket notification pathway. Under 510(k), a manufacturer does not have to show the device works. It has to show the device is substantially equivalent to a device already legally on the market — the "predicate" — in intended use and technological characteristics (FDA, Premarket Notification 510(k)).

The FDA is blunt about the distinction. Its own consumer guidance notes that cleared devices have not been through the approval process, and that "cleared" and "approved" are not interchangeable (FDA, Is It Really "FDA Approved"?).

There is a second wrinkle that almost never appears in clinic copy: the cleared indication on many of these systems is narrow and often has nothing to do with why you're in the chair. Historically, a number of PRP separation devices were cleared for producing platelet-rich plasma to be mixed with bone graft material in orthopedic surgical settings, or for use in wound care — not for injecting into a scalp or a face. You can look up any device's actual cleared indications yourself in the FDA's 510(k) database. Ask the clinic for the manufacturer and model, then read the clearance letter.

"FDA-registered," for what it's worth, means the least of the three. Establishment registration and device listing are administrative filings. They are not a review of anything.

Drug and biologic approval

Drug and biologic approval is the demanding pathway: adequate and well-controlled trials showing a product is safe and effective for a specific condition, at a specific dose, in a specific population. That is the process behind the drug in your medicine cabinet. No PRP product has gone through it for the cosmetic and orthopedic uses PRP is sold for.

Where PRP sits in the regulatory scheme

Autologous PRP — made from your own blood, spun at the point of care, and put back into you the same visit — sits in an unusually light-touch corner of the system.

It generally falls outside the human cells and tissues ("HCT/P") framework that governs things like amniotic and umbilical products, because those regulations specifically exclude whole blood, blood components, and blood derivative products (21 CFR Part 1271). And because the material is your own, minimally processed, and not shipped or sold as a product, it isn't reviewed as a drug or biologic either.

The practical result: the FDA reviews the centrifuge. Nobody reviews whether the injection helps your condition. That judgment falls to your physician, the published literature, and state medical boards that regulate the practice of medicine.

"Off-label" is not a scandal — but it does shift the burden

Using a cleared or approved product for an unapproved purpose is legal, common, and sometimes the standard of care. Physicians do it constantly, and the FDA does not regulate the practice of medicine (FDA, Understanding Unapproved Use of Approved Drugs).

So off-label use is not, by itself, a red flag. What it does mean is that no regulator has independently vetted the claim being made to you. The evidence question moves entirely onto the published research — which, for PRP, is genuinely uneven.

The regulatory gap shows up in the evidence

Because there is no approval process forcing standardization, "PRP" is not one thing. Platelet concentration, white blood cell content, red cell contamination, whether the platelets are activated, spin speed, injection volume, and number of sessions all vary between systems and between clinics. Reviews comparing commercial separation systems have repeatedly found substantially different blood component concentrations from the same starting volume of blood. When two studies of "PRP" test different preparations, comparing their results is partly guesswork.

That heterogeneity is one reason systematic reviews often land on "insufficient evidence." A Cochrane review of platelet-rich therapies for musculoskeletal soft tissue injuries concluded that the evidence was insufficient to support their use, with small trials, inconsistent preparations, and limited functional outcome data (Moraes et al., Cochrane Database of Systematic Reviews).

That is not the same as "PRP does nothing." Some indications have better-quality supporting trials than others, and the literature has grown since. But it is a fair description of how thin the foundation is compared to a treatment that has cleared an approval bar.

Where regulation gets stricter — and where clinics get letters

The light-touch treatment of autologous PRP does not extend outward indefinitely. Combine PRP with something else — an amniotic or umbilical product, exosomes, an expanded or cultured cell population — and you are likely in drug and biologic territory, where marketing without approval is a violation.

The FDA has issued warnings and enforcement actions in this space and maintains consumer alerts about unapproved regenerative medicine products, including stem cell and exosome offerings, some of which have caused serious infections and injuries (FDA, Consumer Alert on Regenerative Medicine Products; FDA, FDA Warns About Stem Cell Therapies).

Safety oversight of the procedure itself is also thinner than patients assume. In 2024, CDC investigators reported apparent HIV transmission among clients of an unlicensed facility offering platelet-rich plasma microneedling — a reminder that the sterility and infection-control practices behind the needle are largely a function of who is holding it, not of federal product review.

What this means for your bill

Regulatory status drives coverage. Because PRP lacks approval for most of the conditions it's marketed for, insurers routinely classify it as investigational and pay nothing. Expect to pay out of pocket, typically in the mid-hundreds to low thousands per session, with multi-session packages running higher — and with wide geographic and specialty variation.

One narrow exception worth knowing: Medicare has, under a national coverage determination, allowed coverage of autologous PRP for certain chronic non-healing wounds under evidence-development conditions. That is a wound-care carve-out, not a general endorsement, and it does not extend to cosmetic or orthopedic use.

Questions worth asking, and copy worth distrusting

Ask:

  • What device and model do you use, and what is its cleared indication?
  • Is my use off-label? (The honest answer is almost always yes.)
  • What platelet concentration does your protocol produce, and how do you know?
  • What published evidence supports this for my specific condition?
  • Is anything being added to my plasma? If so, what, and how is it regulated?

Treat these phrases as warning signs: "FDA-approved PRP," "FDA-approved stem cell therapy," "FDA-registered treatment," or any claim that clearance of a centrifuge validates a clinical result. A provider who blurs clearance and approval is either uninformed about their own regulatory position or comfortable letting you be.

The useful posture here is neither dismissal nor enthusiasm. PRP is a legal, generally low-risk autologous procedure with real but uneven evidence, sold in a regulatory space that does not require anyone to prove it works for you. Knowing that is what lets you ask the right questions.

This guide is information, not medical advice. Decisions about treatment should be made with a licensed clinician who knows your history.